News & Updates

Updated results of the phase II PHAROS study of encorafenib plus binimetinib, a BRAF plus MEK inhibitor combination that has recently become available in Hong Kong, include a median overall survival (mOS) of 47.6 months in treatment-naïve patients and 22.7 months in previously treated patients with BRAF^V600E-mutant metastatic non-small-cell lung cancer (mNSCLC).

Patients with potentially resectable hepatocellular carcinoma (HCC) may receive neoadjuvant nivolumab plus ipilimumab therapy, followed by surgery, to improve their survival, suggests a study.

The combination of adjuvant abemaciclib and endocrine therapy (ET) significantly improves overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer compared with ET alone, the phase III monarchE trial has shown.